TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06908928: A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT06908928 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06908928 Rescue Dossier →